OHR LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ohr Pharmaceutical, Inc. To Contact The Firm

NEW YORK, March 26, 2018 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ohr Pharmaceutical, Inc. (“Ohr” or the “Company”) (NASDAQ:OHRP) of the April 16, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Ohr stock or options between June 24, 2014 and January 4, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/OHRP.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Ohr securities between June 24, 2014 and January 4, 2018 (the “Class Period”). The case, Khanna v. Ohr Pharmaceutical, Inc. et al, No. 18-cv-01284 was filed on February 14, 2018, and has been assigned to Judge Loretta A. Preska.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that the product Squalamine, the company’s lead product candidate for the treatment of wet-AMD, would not produce vision improvements and was commercially not viable.

Specifically, after years of having touted positive clinical results, on January 5, 2018, the Company announced that topline data from its MAKO study to evaluate the use of Squalamine combination therapy for the treatment of wet-AMD did not meet its primary efficacy endpoint.

After the announcement, Ohr’s share price fell from $2.02 per share on January 4, 2018 to a closing price of $0.38 on January 5, 2018—a $1.64 or an 81.2% drop.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ohr’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.